Skip to content

Gradiant can destroy PFAS

Gradiant, a global solutions provider for advanced water and wastewater treatment, today announced a significant advancement in the fight against contamination from PFAS, a persistent chemical. When working with contaminated industrial, municipal, and landfill water, it has been quantitatively proven by several accredited third-party laboratories that PFAS is reduced to below mandated limits by ForeverGone TM and the resulting PFAS concentrate is completely destroyed. This development milestone confirms that ForeverGone, launched earlier this year, is the only complete solution capable of removing and destroying PFAS on-site, eliminating the need for waste treatment, landfilling, or incineration. This also differentiates it from conventional technologies such as granular activated carbon (GAC) or ion exchange. The key advantage: The ForeverGone solution, packaged in containers, can be rapidly deployed and commissioned on-site to effectively reduce PFAS to below...

more »Gradiant can destroy PFAS

WeightWatchers enters the market for weight-loss drugs

  • News

WeightWatchers, the well-known provider of diet programs, is expanding its offerings to include prescription weight-loss drugs. The company will incorporate a compounded version of the popular drug semaglutide into its program. Semaglutide, originally marketed by Novo Nordisk under the name Wegovy, has proven to be highly effective in weight reduction. WeightWatchers is responding to the increasing demand for medication-assisted weight loss. The new service will initially be offered in the United States. Customers can consult via a telemedicine platform and receive a prescription if eligible. The medication will then be compounded by a specialized pharmacy and delivered directly to patients. With this move, WeightWatchers is positioning itself as a holistic provider in the weight management sector. The company emphasizes that the medications should be used in conjunction with behavioral changes and healthy eating. Experts view this move as a response to the success of Novo Nordisk's Wegovy and similar preparations. WeightWatchers...

more »WeightWatchers enters the market for weight-loss drugs

EPA orders nationwide removal of lead pipes

The US Environmental Protection Agency (EPA) has issued a sweeping new regulation mandating the replacement of all lead service lines in the American drinking water system within the next ten years. This measure aims to reduce the health risks associated with lead in drinking water, particularly for children and underserved communities. Scope and Cost The regulation affects an estimated 9.2 million lead service lines nationwide. The total cost for this ambitious project is estimated at $20 billion to $30 billion. To mitigate the financial burden, the Biden administration is providing $15 billion from the Infrastructure Investment and Jobs Act. Health Impacts Lead in drinking water can have serious health consequences, especially for children. It can lead to learning and behavioral problems, reduced IQ, and slowed growth. The EPA expects the new regulation to prevent up to 22,000 cases of lead poisoning in children annually. Challenges and Criticism Despite the health benefits, the regulation also faces criticism. Some… 

more »EPA orders nationwide removal of lead pipes

Laboratory Medicine Benefits from 2024 Nobel Prize in Physics

  • News

The 2024 Nobel Prize in Physics honors groundbreaking research in the field of machine learning and artificial neural networks. Laureates John Hopfield of Princeton University and Geoffrey Hinton of the University of Toronto are recognized for their fundamental discoveries and inventions that enabled machine learning with artificial neural networks[1][2]. Hopfield and Hinton utilized tools from physics to develop methods that laid the foundation for today's powerful machine learning. Hopfield invented a network named after him, which uses a method for storing and retrieving patterns. Hinton built upon this concept and developed the so-called Boltzmann machine, capable of recognizing characteristic elements in specific data types[2]. The laureates' work has far-reaching implications for various scientific disciplines, including physics itself, where artificial neural networks are used, for example, in the development of new materials with specific ...

more »Laboratory Medicine Benefits from 2024 Nobel Prize in Physics

Analysis: The Liquid Biopsy Market

  • News

The liquid biopsy market is showing impressive growth and is expected to continue expanding in the coming years. In 2023, the global market was valued at USD 10.42 billion and is projected to reach USD 20.41 billion by 2030, growing at a compound annual growth rate (CAGR) of 14.23%. The US market is expected to experience even stronger growth, from USD 1.85 billion in 2023 to USD 6.62 billion by 2033, at a CAGR of 13.55%. This growth is driven by several factors, including the rising global cancer prevalence, technological advancements in cancer diagnostics, a growing preference for minimally invasive diagnostic procedures, increasing research and development in the field of liquid biopsy, and rising investments and government initiatives. Looking at market segments, the cancer diagnostics sector dominated in 2023 with a share of 86.26%. In terms of technology, NGS (Next-Generation Sequencing) held the largest market share in 2023…

more »Analysis: The Liquid Biopsy Market

Pathology: Label-free Histology with AI

  • News

A joint research team led by POSTECH Professor Chulhong Kim and Professor Chan Kwon Jung of the Catholic University of Korea's Seoul St. Mary’s Hospital has developed an artificial intelligence (AI) system to analyze label-free photoacoustic histology images of human liver cancer tissue. Their research findings were recently published in “Light: Science and Applications,” an international journal of optics and photonics. Histology is crucial for diagnosing diseases and developing appropriate treatment plans. Typically, removed tissue must be stained under a microscope, which incurs additional labor and costs due to the use of chemicals. Photoacoustic histology (PAH) was developed to mitigate these issues. PAH generates images by detecting sound signals (ultrasound) produced by biomolecules when illuminated with light (laser), making staining and labeling unnecessary. However, pathologists were initially unfamiliar with PAH, which hinders interpretation…

more »Pathology: Label-free Histology with AI

MolecuLight Announces Groundbreaking Study on Antimicrobial Use in Wound Care

MolecuLight, the global leader in fluorescence imaging technology for real-time detection of harmful bacteria in wound care, is pleased to announce the publication of a new study addressing a critical challenge in wound care: the need for standardized and evidence-based prescribing of antibiotics and antimicrobials. This groundbreaking study, published in the journal Diagnostics, underscores the urgent need for widespread adoption of antimicrobial stewardship programs (ASPs) and demonstrates the significant potential for improving prescribing practices with MolecuLight. https://www.mdpi.com/2075-4418/14/18/2034

Discovery of microRNA leads to Nobel Prize

The groundbreaking discovery of microRNA originated from the research of Ambros and Ruvkun on a small roundworm, Caenorhabditis elegans, in the late 1980s and early 1990s. Their work focused on two genes, lin-4 and lin-14, which were crucial for the worm's developmental timing. In 1993, they published their findings in two seminal papers in the journal Cell, demonstrating that lin-4 produced a short RNA sequence that could bind to complementary sequences in the lin-14 mRNA, effectively blocking protein production. This discovery initially met with little resonance in the scientific community, as it was considered a peculiarity of worm biology. However, subsequent research revealed that microRNAs are widespread in nature and play essential roles in gene regulation across various species, including humans. The identification of microRNAs as a new class of regulatory molecules has since transformed our understanding…

more »Discovery of microRNA leads to Nobel Prize

Telekom goes Lab Medicine

In recent years, Deutsche Telekom has developed into a significant player in the field of laboratory medicine by providing innovative IT solutions and digitalization concepts for the healthcare sector. Although Telekom is traditionally known as a telecommunications company, it has greatly expanded its portfolio in the healthcare sector and now offers comprehensive solutions for clinics, laboratories, and other medical facilities[1]. In the field of laboratory medicine, Telekom plays an increasingly important role in networking and digitalizing processes. The company provides platforms and infrastructures that enable laboratories to efficiently process, store, and exchange data. A specific example of this is Telekom's collaboration with vitagroup, offering an open platform in the Open Telekom Cloud[3]. This platform, the HIP Clinical Data Repository (HIP CDR), enables clinics and laboratories to use, centrally store, and… 

more »Telekom goes Lab Medicine

Clinical Development of Lutetium (177Lu) rhPSMA-10.1 Injection

Blue Earth Therapeutics Ltd, an emerging leader in the development of therapeutic radiopharmaceuticals, today announced further positive developments for its novel investigational radioligand therapies. Enrolment of patients in the Phase 1 trial of Lutetium (177Lu) rhPSMA-10.1 Injection was completed in July. Early data from the trial suggests an encouraging safety profile. Radiation dosimetry performed for up to three cycles showed delivery of high tumor absorbed radiation doses relative to the dose delivered to the key normal organs, such as kidney and salivary glands. While final analysis is ongoing, the ratio between radiation dose to tumors vs. dose to the kidneys and salivary glands was compelling vs. published data1 for first generation radioligand therapies. This data opens the way for the Phase 2 portion of the Phase 1/2 trial to start later this year. The company has shared the intended Phase…

more »Clinical Development of Lutetium (177Lu) rhPSMA-10.1 Injection